Research ExplorerPublicationsTrypsinogen activation peptide (TAP) expression in gallbladd...

Trypsinogen activation peptide (TAP) expression in gallbladder bile identifies bilio-pancreatic carcinoma

Standard

Trypsinogen activation peptide (TAP) expression in gallbladder bile identifies bilio-pancreatic carcinoma. / Brockmann, Jens G; Hernandez, Carlos A; Emparan, Carlos; Wolters, Heiner; Haier, Jörg; Dietl, Karl-Heinz; Senninger, Norbert J.

In: ANTICANCER RES, Vol. 23, No. 2A, 25.06.2003, p. 819-25.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Brockmann, JG, Hernandez, CA, Emparan, C, Wolters, H, Haier, J, Dietl, K-H & Senninger, NJ 2003, 'Trypsinogen activation peptide (TAP) expression in gallbladder bile identifies bilio-pancreatic carcinoma', ANTICANCER RES, vol. 23, no. 2A, pp. 819-25.

APA

Brockmann, J. G., Hernandez, C. A., Emparan, C., Wolters, H., Haier, J., Dietl, K-H., & Senninger, N. J. (2003). Trypsinogen activation peptide (TAP) expression in gallbladder bile identifies bilio-pancreatic carcinoma. ANTICANCER RES, 23(2A), 819-25.

Vancouver

Brockmann JG, Hernandez CA, Emparan C, Wolters H, Haier J, Dietl K-H et al. Trypsinogen activation peptide (TAP) expression in gallbladder bile identifies bilio-pancreatic carcinoma. ANTICANCER RES. 2003 Jun 25;23(2A):819-25.

Bibtex

@article{83285765da394240a2aa6c104790086d,
title = "Trypsinogen activation peptide (TAP) expression in gallbladder bile identifies bilio-pancreatic carcinoma",
abstract = "BACKGROUND: The prognosis of bilio-pancreatic cancer (pancreas, bile duct and gallbladder) is poor due to the fact of late diagnosis. The only curative treatment for such tumors is surgery. The 5-year survival rate is still below 5% and less than one-third of patients suffering from such carcinomas are resectable at the time of diagnosis. Although specific tumor markers do exist, to date there is no screening marker for these diseases.MATERIALS AND METHODS: Gallbladder bile of 44 consecutive cholecystectomized patients were prospectively analyzed for TAP concentrations. Group one (n = 14) consisted of the patients suffering from malignancies of the bilio-pancreatic system, group 2 (n = 22) comprised patients suffering from benign biliar or pancreatic diseases and group 3 (n = 6) included patients suffering from gastrointestinal carcinoma outside the bilio-pancreatic system with no affection of the bilio-pancreatic system.RESULTS: The median TAP gallbladder bile concentration in malignant disease of the bilio-pancreatic system was 1328.00 nmol/l (range: 83.69-5133.00). Benign bilio-pancreatic disease revealed a median TAP bile concentration of 2.02 nmol/l equaling the concentration of patients suffering from other gastrointestinal carcinomas with a median of 2.00 nmol/l. In the control groups (2 + 3) there was a significant difference for TAP bile concentrations with an increase in the case of acute inflammation.CONCLUSION: Gallbladder bile TAP concentration discriminates between benign and malignant lesions of the bilio-pancreatic system. In the case of benign disease there is a significantly higher TAP concentration in the case of acute inflammation.",
keywords = "Bile, Bile Duct Neoplasms, Biliary Tract Diseases, Biliary Tract Neoplasms, Biomarkers, Tumor, Humans, Middle Aged, Oligopeptides, Pancreatic Diseases, Pancreatic Neoplasms, Reference Values, Trypsinogen",
author = "Brockmann, {Jens G} and Hernandez, {Carlos A} and Carlos Emparan and Heiner Wolters and J{\"o}rg Haier and Karl-Heinz Dietl and Senninger, {Norbert J}",
year = "2003",
month = jun,
day = "25",
language = "English",
volume = "23",
pages = "819--25",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2A",

}

RIS

TY - JOUR

T1 - Trypsinogen activation peptide (TAP) expression in gallbladder bile identifies bilio-pancreatic carcinoma

AU - Brockmann, Jens G

AU - Hernandez, Carlos A

AU - Emparan, Carlos

AU - Wolters, Heiner

AU - Haier, Jörg

AU - Dietl, Karl-Heinz

AU - Senninger, Norbert J

PY - 2003/6/25

Y1 - 2003/6/25

N2 - BACKGROUND: The prognosis of bilio-pancreatic cancer (pancreas, bile duct and gallbladder) is poor due to the fact of late diagnosis. The only curative treatment for such tumors is surgery. The 5-year survival rate is still below 5% and less than one-third of patients suffering from such carcinomas are resectable at the time of diagnosis. Although specific tumor markers do exist, to date there is no screening marker for these diseases.MATERIALS AND METHODS: Gallbladder bile of 44 consecutive cholecystectomized patients were prospectively analyzed for TAP concentrations. Group one (n = 14) consisted of the patients suffering from malignancies of the bilio-pancreatic system, group 2 (n = 22) comprised patients suffering from benign biliar or pancreatic diseases and group 3 (n = 6) included patients suffering from gastrointestinal carcinoma outside the bilio-pancreatic system with no affection of the bilio-pancreatic system.RESULTS: The median TAP gallbladder bile concentration in malignant disease of the bilio-pancreatic system was 1328.00 nmol/l (range: 83.69-5133.00). Benign bilio-pancreatic disease revealed a median TAP bile concentration of 2.02 nmol/l equaling the concentration of patients suffering from other gastrointestinal carcinomas with a median of 2.00 nmol/l. In the control groups (2 + 3) there was a significant difference for TAP bile concentrations with an increase in the case of acute inflammation.CONCLUSION: Gallbladder bile TAP concentration discriminates between benign and malignant lesions of the bilio-pancreatic system. In the case of benign disease there is a significantly higher TAP concentration in the case of acute inflammation.

AB - BACKGROUND: The prognosis of bilio-pancreatic cancer (pancreas, bile duct and gallbladder) is poor due to the fact of late diagnosis. The only curative treatment for such tumors is surgery. The 5-year survival rate is still below 5% and less than one-third of patients suffering from such carcinomas are resectable at the time of diagnosis. Although specific tumor markers do exist, to date there is no screening marker for these diseases.MATERIALS AND METHODS: Gallbladder bile of 44 consecutive cholecystectomized patients were prospectively analyzed for TAP concentrations. Group one (n = 14) consisted of the patients suffering from malignancies of the bilio-pancreatic system, group 2 (n = 22) comprised patients suffering from benign biliar or pancreatic diseases and group 3 (n = 6) included patients suffering from gastrointestinal carcinoma outside the bilio-pancreatic system with no affection of the bilio-pancreatic system.RESULTS: The median TAP gallbladder bile concentration in malignant disease of the bilio-pancreatic system was 1328.00 nmol/l (range: 83.69-5133.00). Benign bilio-pancreatic disease revealed a median TAP bile concentration of 2.02 nmol/l equaling the concentration of patients suffering from other gastrointestinal carcinomas with a median of 2.00 nmol/l. In the control groups (2 + 3) there was a significant difference for TAP bile concentrations with an increase in the case of acute inflammation.CONCLUSION: Gallbladder bile TAP concentration discriminates between benign and malignant lesions of the bilio-pancreatic system. In the case of benign disease there is a significantly higher TAP concentration in the case of acute inflammation.

KW - Bile

KW - Bile Duct Neoplasms

KW - Biliary Tract Diseases

KW - Biliary Tract Neoplasms

KW - Biomarkers, Tumor

KW - Humans

KW - Middle Aged

KW - Oligopeptides

KW - Pancreatic Diseases

KW - Pancreatic Neoplasms

KW - Reference Values

KW - Trypsinogen

M3 - SCORING: Journal article

C2 - 12820306

VL - 23

SP - 819

EP - 825

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 2A

ER -